Randomized placebo-and active controlled study of eplivanserin, a novel sleep agent, on next-day psychomotor and cognitive tasks in healthy subjects

被引：0
|
作者：
Micallef-Roll, J.
Roy, C.
Delfolie, A.
Pinquier, J. L.
Blin, O.
机构：
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2009年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
544
引用
收藏
页码：108 / 108
页数：1
相关论文
共 50 条
  • [41] Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects
    Sun, Cheng
    Liu, Hao
    Ouyang, Ziwei
    Ding, Jie
    Zhang, Qin
    Ma, Hongjie
    Xu, Dandan
    Zhang, Qian
    Zhou, Renpeng
    Yang, Mingming
    Hu, Wei
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (05) : 533 - 542
  • [42] CSL112, a Novel Formulation of Human Apolipoprotein A-I, Dramatically Increases Cholesterol Efflux Capacity in Healthy Subjects: A, Placebo-Controlled, Double-Blinded, Randomized Single Ascending Dose Study
    Gille, Andreas
    Easton, Rachael
    Wright, Samuel
    Shear, Charles
    CIRCULATION, 2012, 126 (21)
  • [43] Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1-Infected Subjects
    Cotte, Laurent
    Dellamonica, Pierre
    Raffi, Francois
    Yazdanpanah, Yazdan
    Molina, Jean-Michel
    Boue, Francois
    Urata, Yasuo
    Chan, H. Phyllis
    Zhu, Li
    Chang, Ih
    Bertz, Richard
    Hanna, George J.
    Grasela, Dennis M.
    Hwang, Carey
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (03) : 346 - 354
  • [44] Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects
    Liu, Jian
    Zhao, Qingwei
    Zhai, You
    Wu, Xia
    Kai, Jiejing
    Ruan, Jie
    Wu, Minglan
    Wu, Meijia
    Zhou, Zhuojun
    Yan, Yuemei
    Wu, Jinzi J.
    Qiu, Yunqing
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024,
  • [45] CSL112, a Novel Formulation of Human Apolipoprotein A-I, Provides Sustained Increases in Biomarkers of Cholesterol Transport Following Repeat Dosing: A Placebo-Controlled, Randomized Multiple Ascending Dose Study in Healthy Subjects
    Gille, Andreas
    Easton, Rachael
    Wright, Samuel
    Shear, Charles
    CIRCULATION, 2012, 126 (21)
  • [46] Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200 mg/50 mg Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects
    Vaz-da-Silva, Manuel
    Loureiro, Aua I.
    Nunes, Teresa
    Lopes, Carlos
    Rocha, Jose
    Machado, Rita
    Costa, Raquel
    Torrao, Leonel
    Falcao, Amilcar
    Wright, Lyndon
    Almeida, Luis
    Soares-da-Silva, Patricio
    DRUGS IN R&D, 2008, 9 (06) : 435 - 446
  • [47] RESULTS OF A PHASE 1, 4-PERIOD CROSSOVER, PLACEBO-CONTROLLED, RANDOMIZED, SINGLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-925, A NOVEL OREXIN 2 RECEPTOR AGONIST, IN SLEEP-DEPRIVED HEALTHY ADULTS, UTILIZING MODAFINIL AS AN ACTIVE COMPARATOR
    Evans, R.
    Hazel, J.
    Faessel, H.
    Wu, J.
    Hang, Y.
    Alexander, R.
    Rosen, L.
    Hartman, D.
    SLEEP MEDICINE, 2019, 64 : S106 - S106
  • [48] A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ASCENDING SINGLE-DOSE, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AMG 529, A NOVEL ANTI-ASGR1 MONOCLONAL ANTIBODY, IN HEALTHY SUBJECTS
    Janiszewski, Mariano
    Sohn, Winnie
    Su, Cheng
    Hsu, Yi Hsiang
    Finger, Elizabeth
    Kaufman, Allegra
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1755 - 1755
  • [49] A Phase I, single-blind, placebo-controlled, ascending single oral dose, safety, tolerability and pharmacokinetic study of CDC-501, a novel immunomodulatory-oncologic agent, in healthy male subjects with a comparison of fed and fasted.
    Teo, SK
    Oliver, S
    Harden, J
    Stirling, D
    Thomas, S
    Scheffler, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P93 - P93
  • [50] ASC42, A NOVEL NON-STEROIDAL FXR AGONIST, DEMONSTRATES A NORMAL CHOLESTEROL PROFILE AND LACK OF PRURITUS AT THERAPEUTIC DOSES IN A 14-DAY PHASE I RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY IN HEALTHY VOLUNTEERS
    Palmer, Melissa
    He, Handan
    Wu, Jinzi
    HEPATOLOGY, 2021, 74 : 1102A - 1102A
12345